Biomarker predicts KRASG12C inhibitor success in lung cancer treatment
A new study from Moffitt Cancer Center could help doctors predict how well patients with a specific type of lung cancer will respond to new therapies. The research, published in Clinical Cancer ...
News Medical3h
Researchers develop T cell growth method that enhances cancer-fighting ability in melanoma model
Findings indicate that altering glucose metabolism in T cells boosts their therapeutic potential against melanoma, paving the ...
Targeted Oncology3h
Poor Outcomes Seen in BRAF V600E-Mutant mCRC With Systemic Therapy
Patients with BRAF V600E-mutant metastatic colorectal cancer experienced poor clinical outcomes with systemic therapy, ...
EurekAlert!2d
In HER2+ colorectal cancer, anti-HER2 therapy may be less toxic alternative
A phase 2 trial finds that for patients with HER2+ metastatic colorectal cancer, dual HER2-inhibitor therapy can be a similarly efficacious but less toxic alternative to EGFR inhibitor therapy.
Medpage Today on MSN5d
Triple Therapy in Metastatic CRC With BRAF Mutations: The New Standard of Care?
First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant ...